2003 was an up and down year for proteomics: Academic and clinical researchers made out well — spurred by hefty NIH funding initiatives, instrument vendors courting customers, HUPO’s expansion, and an explosion of interest in proteomics biomarker discovery — while technology start-ups continued to fumble for footing, and large instrument companies merged and reorganized their marketing strategies to stress product integration.

NIH Funding Strong